Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia

Current Medical Research and Opinion

Volumn 28, Issue 5, 2012, Pages 815-821

  Saxe, Philippe A ^a   Arnold, Lesley M ^b   Palmer, Robert H ^c   Gendreau, R Michael ^d   Chen, Wei ^c  

^a Arthritis Associates of South Florida   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Gendreau Consulting   (United States)

Author keywords

Discontinuation; Fibromyalgia; Milnacipran; Pain; Physical function

Indexed keywords

CREATINE KINASE; MILNACIPRAN;

ARTICLE; ATTENTION DISTURBANCE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; FUNCTIONAL STATUS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; VITAL SIGN; VOMITING;

ADULT; BLOOD PRESSURE; CYCLOPROPANES; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN; TREATMENT OUTCOME;

EID: 84861181740     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.677418     Document Type: Article

References (24)

1. Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997;40:1571-9 (Pubitemid 27426149)
2. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72 (Pubitemid 20098653)
4. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005;32:2270-7 (Pubitemid 41587880)
5. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009;36:2318-29
6. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebocontrolled trial. J Rheumatol 2009;36:398-409 [published correction appears in J Rheumatol 2009;36:661]
7. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004 [published correction appears in Clin Ther 2009;31:446]
8. Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9
9. Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2745-56
10. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33
11. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
12. Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25
13. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
14. Seidenberg M, Haltiner A, Taylor MA, et al. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 1994;16:93-104 (Pubitemid 24051080)
15. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21 (Pubitemid 351147828)
16. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58 (Pubitemid 33016608)
17. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54
18. Dunkl PR, Taylor AG, McConnell GG, et al. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91
19. Cymbalta [package insert]. Indianapolis, IN, USA: Eli Lilly and Company, September 2011. Available at: www.cymbalta.com [Last accessed 19 January 2012]
20. Savella [package insert]. St. Louis, MO, USA: Forest Laboratories, Inc., November 2011. Available at: www.savella.com [Last accessed 10 January 2012]
21. Clauw DJ, Mease PJ, Ma Y, et al. Continuing efficacy of milnacipran demonstrated after long-term treatment of fibromyalgia [abstract]. Arthritis Rheum 2011;63:S365
22. Mease PJ, Clauw DJ, Ma Y, et al. Return of pain and functional impairment after discontinuation of milnacipran in patients with fibromyalgia [abstract]. Arthritis Rheum 2011;63:S742
23. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13:27-33
24. Forest Research Institute, Inc. Data on file